Please login to the form below

Not currently logged in
Email:
Password:

TT701

This page shows the latest TT701 news and features for those working in and with pharma, biotech and healthcare.

Transition takes on Lilly muscle-boosting drug

Transition takes on Lilly muscle-boosting drug

The big pharma company pockets just $1m upfront from the deal, although Transition could pay up to $100m in milestones if the small-molecule drug - called TT701 - eventually reaches the market. ... TT701 is a selective androgen receptor modulator (SARM)

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    Transition Therapeutics with the out-licence of the phase II ready selective androgen receptor modulator TT701 to Transition. ... 105.5. Eli Lilly/ Transition Therapeutics. Licence agreement. For TT701 a selective androgen receptor modulator in P2 for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics